GlassScriptPhysician profile
Jissy R Philip
NPI 1548524424
$1,263.92
in general payments reported to CMS, 2019-2025
20 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $24.75 · 2021: $65.36 · 2022: $268 · 2023: $329 · 2024: $266 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $250.61 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $123.52 | 2023-2024 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $105.14 | 2019-2025 | |
| Novo Nordisk INC | $99.20 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $88.80 | 2019-2024 | Farxiga, Breztri |
| Abbvie INC. | $85.94 | 2022-2025 | |
| Glaxosmithkline, LLC. | $83.80 | 2020-2023 | Shingrix, Bexsero, Pediarix |
| Dexcom, INC. | $79.24 | 2023-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.97 | 2022-2025 | Jardiance |
| Organon LLC | $44.24 | 2023-2025 | Nexplanon |
| Amarin Pharma, INC. | $36.11 | 2019-2021 | |
| Astellas Pharma US INC | $35.62 | 2024-2025 | Veozah |
| Dynavax Technologies Corporation | $31.22 | 2024-2025 | Heplisav-B |
| Axsome Therapeutics, INC. | $23.76 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.15 | 2024 | Xifaxan |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $20.80 | 2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $19.91 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.52 | 2025 | |
| Exact Sciences Corporation | $14.44 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $13.93 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jissy Philip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.